RxDoctor Payments Data

Heather Schrof, MD

Family Medicine · Port Charlotte, FLNPI 1578656831

Payments from drug & device makers

$2,523in general payments, 2019–2025

Across 125 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$455
  • Novo Nordisk$439
  • AbbVie$318
  • GSK$250
  • Eisai Inc.$157
  • Lilly USA, LLC$155
  • plus $747 from 16 others

What the payments were for

  • Food & beverage$2,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,523 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$450,046
Medicare patients
907
Services billed
12,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$208,466
OzempicSemaglutide103$125,535
JardianceEmpagliflozin70$102,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$100,251
MounjaroTirzepatide59$72,700
XareltoRivaroxaban36$47,117
JanuviaSitagliptin Phosphate38$45,913
TrulicityDulaglutide23$34,335
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$31,580
Breo ElliptaFluticasone/Vilanterol36$31,393
LinzessLinaclotide35$31,319
Tresiba Flextouch U-100Insulin Degludec28$23,708
RybelsusSemaglutide21$23,134
Spiriva HandihalerTiotropium Bromide14$20,317
FarxigaDapagliflozin Propanediol13$19,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$69$218,427204 claims
Novo NordiskOzempic, Rybelsus$439$148,669124 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$250$148,353156 claims
Lilly USA, LLCMounjaro, Trulicity$155$107,03682 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$71$60,27586 claims
AbbVieLinzess, Synthroid$318$38,063161 claims
Astellas Pharma US IncMyrbetriq$85$17,60620 claims
NovartisEntresto$14$13,03515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →